通过多组学亚克隆分析解析多发性骨髓瘤的治疗耐药机制
本研究对15例复发或难治性多发性骨髓瘤患者的纵向样本整合全基因组测序、单细胞转录组学、染色质可及性及线粒体DNA突变,定义亚克隆结构与演化。研究发现治疗耐药由三种并行机制构成:亚克隆预存表观遗传生存优势、遗传不同亚克隆的表型趋同适应、亚克隆特异性骨髓微环境相互作用。
要点
- 对15例复发或难治性多发性骨髓瘤患者的纵向样本行多组学整合分析。
- 治疗耐药涉及预存表观遗传优势、表型趋同适应和微环境亚克隆特异性互作。
- 整合多组学可追踪并表征不同多药耐药亚克隆以识别分子靶点。
核心结论
- 整合多组学分析可追踪并表征随时间出现的不同多药耐药亚克隆,以识别针对它们的分子靶点。
研究设计与样本
- 对15例复发或难治性多发性骨髓瘤患者的纵向样本整合全基因组测序、单细胞转录组学、染色质可及性测序及线粒体DNA突变,定义亚克隆结构与演化。
主要发现
- 治疗耐药涉及三种并行机制:亚克隆预存表观遗传谱与生存优势相关。
- 治疗耐药涉及遗传不同的亚克隆发生趋同的表型适应。
- 治疗耐药涉及骨髓瘤与骨髓微环境细胞之间的亚克隆特异性相互作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Intratumor heterogeneity as a clinical challenge becomes most evident after several treatment lines, when multidrug-resistant subclones accumulate. To address this challenge, the characterization of resistance mechanisms at the subclonal level is key to identify common vulnerabilities. In this study, we integrate whole-genome sequencing, single-cell (sc) transcriptomics (scRNA sequencing), and chromatin accessibility (scATAC sequencing) together with mitochondrial DNA mutations to define subclonal architecture and evolution for longitudinal samples from 15 patients with relapsed or refractory multiple myeloma. We assess transcriptomic and epigenomic changes to resolve the multifactorial nature of therapy resistance and relate it to the parallel occurrence of different mechanisms: (1) preexisting epigenetic profiles of subclones associated with survival advantages, (2) converging phenotypic adaptation of genetically distinct subclones, and (3) subclone-specific interactions of myeloma and bone marrow microenvironment cells. Our study showcases how an integrative multiomics analysis can be applied to track and characterize distinct multidrug-resistant subclones over time for the identification of molecular targets against them.
引用
- Poos AM, Prokoph N, Przybilla MJ, et al. Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis. Blood. 2023. PMID: 37390336. doi:10.1182/blood.2023019758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。